EC
AKCA

EcoR1 Capital’s Akcea Therapeutics Inc AKCA Stock Holding History

EcoR1 Capital’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-639,743
Closed -$19.3M – 58
2018
Q4 		$19.3M Sell
639,743
-115,377
-15% -$3.23M 1.93% 17
2018
Q3 		$26.4M Buy
+755,120
New +$22.8M 2.38% 12

Other funds holding AKCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SC
Sculptor Capital New York $12.3B AUM 40.26% 1-Year Est. Return

EcoR1 Capital's AKCA Position: Q1 2019 in Review

EcoR1 Capital sold out of Akcea Therapeutics Inc (AKCA) in Q1 2019, closing a stake of 639,743 shares — an estimated $19.3M sold.

EcoR1 Capital first reported a position in AKCA in Q3 2018 and held it in 2 quarters. The position peaked at $26.4M in Q3 2018. 74 funds tracked by Wall St. Rank hold AKCA as of Q1 2019.

  • EcoR1 Capital reported no remaining Akcea Therapeutics Inc position as of Q1 2019 after selling out during the quarter.
  • EcoR1 Capital sold 639,743 Akcea Therapeutics Inc shares in Q1 2019, an estimated $19.3M.
  • EcoR1 Capital first reported a position in Akcea Therapeutics Inc in Q3 2018 and held it in 2 quarters.
  • EcoR1 Capital's Akcea Therapeutics Inc position peaked at $26.4M in Q3 2018.
  • 74 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q1 2019.

Based on EcoR1 Capital's 13F filing for Q1 2019, filed 15 May 2019.